Peak cyclosporine levels (C(max)) correlate with freedom from liver graft rejection: Results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8)

Transplantation

Volumn 67, Issue 8, 1999, Pages 1133-1137

  Grant, D ^a   Kneteman, N ^b   Tchervenkov, J ^c   Roy, A Roy, ^d   Murphy, G ^e   Tan, A ^e   Hendricks, L ^e   Guilbault, N ^e   Levy, G ^f  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

^e Novartis Pharma Canada   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; COUGHING; DISEASE MARKER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; EDEMA; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MEAN RESIDENCE TIME; ORAL DRUG ADMINISTRATION; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CYCLOSPORINE; DOUBLE-BLIND METHOD; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033609074     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199904270-00008     Document Type: Article

References (11)

1. Mueller EA, Kovarid JM, van Bree JB, Tetzloff W, Grevel J, Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11(2): 301.
2. Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83(3): 444.
3. Mueller EA, Kovarik JM, van Bree JB, Lison AE, Kutz K. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients: a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57(8): 1178.
4. Wahlberg J, Wilczek HE, Fauchald P, et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant patients over a one year study period. Transplantation 1995; 60(7): 648.
5. Keown P, Landsberg D, Halloran P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Transplantation 1996; 62(12): 1744.
6. Freeman D, Grant D, Levy G, et al. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. Ther Drug Monit 1995; 17(3): 213.
7. Grant D, Rochon J, Levy G. Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group. Transplant Proc 1996; 28(4): 2232.
8. Hemming AW, Grieg PD, Cattral MS, et al. A microemulsion of cyclosporine without intravenous cyclosporine in liver transplantation. Transplantation 1996; 62(12): 1798.
9. Tredger JM. Using cyclosporine Neoral immediately after liver transplantation. Ther Drug Monit 1995; 17: 638.
10. Levy G, Rasmussen A, Mayer AD, Jamieson NV, Neuhaus P. Neoral in de novo liver transplantation: adequate immunosuppression without intravenous cyclosporine. Liver Transpl Surg 1997; 3(6): 571.
11. Batiuk TD, Pazderka F, Enns J, DeCastro L, Halloran PF. Cyclosporine inhibition of calcineurin activity in human lymphocytes in vivo is rapidly reversible. J Clin Invest 1995; 96: 1254.